Stylianos Georgiadis

Glostrup, 2600, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Correction: Clinical and MRI remission in axial spondyloarthritis: one-year outcomes and predictors from the TRACE treat-to-target study with secukinumab.

Correction: Clinical and MRI remission in axial spondyloarthritis: one-year outcomes and predictors from the TRACE treat-to-target study with secukinumab.

Journal: Arthritis research & therapy

Published: July 18, 2026

The impact of smoking and obesity on secukinumab effectiveness in psoriatic arthritis: real-world evidence from 1202 European patients.

The impact of smoking and obesity on secukinumab effectiveness in psoriatic arthritis: real-world evidence from 1202 European patients.

Journal: EULAR rheumatology open

Published: June 29, 2026

Overall and Sex-Specific Predictors of Secukinumab Effectiveness in European Patients With Psoriatic Arthritis: Results From the EuroSpA Collaboration.

Overall and Sex-Specific Predictors of Secukinumab Effectiveness in European Patients With Psoriatic Arthritis: Results From the EuroSpA Collaboration.

Journal: The Journal of rheumatology

Published: June 15, 2026

Overall and sex-specific predictors of secukinumab effectiveness in European patients with psoriatic arthritis: results from the EuroSpA collaboration.

Overall and sex-specific predictors of secukinumab effectiveness in European patients with psoriatic arthritis: results from the EuroSpA collaboration.

Journal: The Journal of rheumatology

Published: June 15, 2026

Clinical and MRI remission in axial spondyloarthritis: one-year outcomes and predictors from the TRACE treat-to-target study with secukinumab.

Clinical and MRI remission in axial spondyloarthritis: one-year outcomes and predictors from the TRACE treat-to-target study with secukinumab.

Journal: Arthritis research & therapy

Published: February 07, 2026

Effect of secukinumab dose escalation on MRI-detected inflammation and structural damage in axial spondyloarthritis: a clinical, investigator-initiated, treat-to-target study (TRACE).

Effect of secukinumab dose escalation on MRI-detected inflammation and structural damage in axial spondyloarthritis: a clinical, investigator-initiated, treat-to-target study (TRACE).

Journal: RMD open

Published: January 27, 2026

Defining and validating a high specificity MRI cut-off for the radiographic part of the modified New York criteria in patients with axial spondyloarthritis.

Defining and validating a high specificity MRI cut-off for the radiographic part of the modified New York criteria in patients with axial spondyloarthritis.

Journal: Arthritis research & therapy

Published: January 06, 2026

Structural damage assessment in the spine of patients with axial spondyloarthritis - results from an international OMERACT multi-reader exercise using MRI-based synthetic CT.

Structural damage assessment in the spine of patients with axial spondyloarthritis - results from an international OMERACT multi-reader exercise using MRI-based synthetic CT.

Journal: Seminars in arthritis and rheumatism

Published: November 19, 2025

Patterns of spinal new bone formation in patients with axial spondyloarthritis, psoriatic arthritis, rheumatoid arthritis and healthy controls: a low-dose CT study.

Patterns of spinal new bone formation in patients with axial spondyloarthritis, psoriatic arthritis, rheumatoid arthritis and healthy controls: a low-dose CT study.

Journal: RMD open

Published: October 03, 2025

Defining Bath Ankylosing Spondylitis Disease Activity Index Cut-off Values for Disease Activity States in a Multinational European Cohort of Patients With Axial Spondyloarthritis.

Defining Bath Ankylosing Spondylitis Disease Activity Index Cut-off Values for Disease Activity States in a Multinational European Cohort of Patients With Axial Spondyloarthritis.

Journal: ACR open rheumatology

Published: April 17, 2025

Predictors of Secukinumab Treatment Response and Continuation in Axial Spondyloarthritis: Results From the EuroSpA Research Collaboration Network.

Predictors of Secukinumab Treatment Response and Continuation in Axial Spondyloarthritis: Results From the EuroSpA Research Collaboration Network.

Journal: The Journal of rheumatology

Published: January 02, 2025

Interchangeability of patient pain, fatigue and global scores in patients with spondyloarthritis - a registry-based simulation study.

Interchangeability of patient pain, fatigue and global scores in patients with spondyloarthritis - a registry-based simulation study.

Journal: BMC rheumatology

Published: December 05, 2024

Showing 1-12 of 36

Last Updated: 09/26/2026